🕒 Last update: loading…

Stock WORK Medical Technology Group Ltd. Class A WOK

WORK Medical Technology Group Ltd. Class A — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2024 → 2025: -100.00%

Price change 2025 → 2026: -99.19%

Price change 2026 (year to date): -99.24%

Financial growth

Revenue CAGR (6 years): -28.45%

Earnings CAGR (6 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 0.35

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio not available.

Correction (6 months)

Current correction: 99.74% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
WORK Medical Technology Group Ltd.–0.35−28.4 %🔒
Spineway S.A.–0.07+9.3 %–
CompuMed, Inc.–0.23+10.2 %–
SpineGuard S.A.–0.27+1.6 %–
Daré Bioscience, Inc.–0.93+9.1 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by WORK Medical Technology Group Ltd. Class A over the latest fiscal years.

Revenue
9.8 m USD
fiscal year 2025
Net income
-1.1 m USD
fiscal year 2025
Net margin
-10.9 %
fiscal year 2025
Average annual growth
-28.5 %
Revenue growth over 5 years
Market cap
2.9 m USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
202052.5 m1.2 m2.2 %n/a
202145.9 m6.0 m13.0 %-12.7 %
202219.7 m865,2104.4 %-57.0 %
202313.6 m112,0300.8 %-31.2 %
202411.5 m-3.5 m-30.4 %-15.2 %
20259.8 m-1.1 m-10.9 %-14.4 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by WORK Medical Technology Group Ltd. Class A over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
0.24
risk zone (below 1.81)
Piotroski Score
3 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
-1.06 x
net cash
Fiscal year20212022202320242025
Cash and investments508,708731,1781.6 m6.6 m4.1 m
Total Debt6.6 m6.3 m9.1 m13.5 m6.4 m
Net Debt6.1 m5.6 m7.5 m6.9 m2.4 m
Equity10.0 m10.0 m9.9 m13.2 m18.3 m
Total assets30.7 m25.5 m30.0 m36.3 m33.2 m
Operating cash flow-7.2 m-2.3 m2.2 m-2.2 m6.2 m
Investments (capex)60,0002.0 m455,3919.2 m1.3 m
Free cash-flow-7.2 m-4.3 m1.6 m-11.5 m4.9 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-0.01 x
Return on Equity (ROE)-18.6 %
Return on Invested Capital (ROIC)-11.4 %
Net margin-42.0 %
Debt / equity0.22 x
Current ratio1.37 x
Interest coverage-13.35 x
Free cash-flow yield-186.1 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 18/11/2026.

+

Valuation and competitors

WORK Medical Technology Group Ltd. Class A compared with its sector on the same exchange and with its main competitors.

Sector median P/E
20.8
healthcare, Nasdaq
Sector over 10 years
28.2
10-year median, range 20.4 to 45.8

Direct competitors

CompanyMarket cap (USD)P/ENet margin
WORK Medical Technology Group Ltd. Class A2.9 mn/a-10.9 %
Lipella Pharmaceuticals Inc. LIPO2,773n/an/a
Silexion Therapeutics Ltd. SLXN52,296n/a0.0 %
Indaptus Therapeutics, Inc. INDP359 mn/a0.0 %
Protagenic Therapeutics, Inc. PTIX832,696n/a0.0 %
SciSparc Ltd. SPRC205,142n/a-1,422.8 %
Mobile-health Network Solutions Class A Ordinary Shares MNDR23,256n/a-44.2 %
Artelo Biosciences, Inc. ARTL7.2 mn/a0.0 %
Jasper Therapeutics, Inc. JSPR15.2 mn/a0.0 %
Sector median (Nasdaq)20.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Dividends and earnings

WORK Medical Technology Group Ltd. Class A: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Stock splits

DateOperation
18/06/2026reverse split: 1 share for 100
29/12/2025reverse split: 1 share for 100
21/10/2025reverse split: 1 share for 100

Factual data: ex-dividend history and earnings calendar, as of 18/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in WORK Medical Technology Group Ltd. Class A.

Free float
0.4 %
share of freely traded shares

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 14/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 23/08/2024
ISIN code
KYG9767H1092
Workforce
216
full-time employees
Chief executive
Shuang Wu

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about WORK Medical Technology Group Ltd. Class A

What is the WORK Medical Technology Group Ltd. Class A share price?

Latest recorded price: 1.20 USD on 13/11/2026, for a market cap of 2.9 m USD.

What is the revenue of WORK Medical Technology Group Ltd. Class A?

9.8 m USD for fiscal year 2025, with net income of -1.1 m USD (net margin -10.9 %).

Is WORK Medical Technology Group Ltd. Class A stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN KYG9767H1092).

How many employees does WORK Medical Technology Group Ltd. Class A have?

216 full-time employees according to the latest published profile.

Who runs WORK Medical Technology Group Ltd. Class A?

Shuang Wu is the company's chief executive.

07

Similar stocks